EL7.AI
StocksMedium•17 November 2026•
3 min read

European Commission Grants Adcomfo Authorization; Register Names Advanz Pharma as License Holder

Key Facts

1Amneal reported third-quarter 2026 revenue of $863 million, up 10% year over year.
2Amneal recorded a net loss of $22 million in the third quarter of 2026, compared with net income of $2 million a year earlier.
3Adjusted EBITDA rose to $207 million, up 30%.
4The company raised its 2026 revenue outlook to a range of $3.15–$3.25 billion.
5AMRX shares closed at $21.23 on November 16, 2026.

The European Commission has granted marketing authorization for Adcomfo, a biosimilar to XOLAIR, according to the Commission’s register. The register identifies Advanz Pharma Limited as the marketing authorization holder in the European Union. The European Medicines Agency’s approval covers the drug’s use to treat severe allergic asthma and chronic spontaneous urticaria, as well as chronic rhinosinusitis with nasal polyps. The decision comes as Amneal expands its biosimilars business, but the authorization register does not name it as the European license holder. The regulatory details therefore center on the identity of the license holder and the scope of approved uses, alongside a commercial link that could not be verified.

Adcomfo’s approval places the product in the competition for treatments based on XOLAIR, with authorized use spanning three conditions: severe allergic asthma, chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps. The European Medicines Agency lists these conditions among the drug’s indications. This scope means the decision covers not only asthma and urticaria but also patients with sinusitis accompanied by nasal polyps. Available information does not provide details on the timing of a commercial launch or European marketing arrangements. The Commission’s register also does not identify Amneal’s share of potential product revenue.

The regulatory development coincides with growth in Amneal’s business in the third quarter of 2026. The company reported revenue of $863 million, up 10% from $785 million in the third quarter of 2025, according to its financial results. The company said its net loss attributable to it under generally accepted accounting principles was $22 million, compared with net income of $2 million in the year-earlier period. Amneal attributed the loss to nonrecurring acquisition and integration costs and a higher tax provision. The figures therefore show revenue growth alongside a year-over-year decline in the bottom line.

On an adjusted earnings basis, Amneal reported third-quarter adjusted EBITDA of $207 million, up 30% from the same period in 2025, according to its results statement. The company attributed the improvement to higher revenue and gross profit, as well as lower operating expenses. The measure adds context to the GAAP net loss, indicating improvement in the adjusted operating metric alongside acquisition and integration costs and the tax provision. Available information did not link this performance to Adcomfo revenue or the timing of its financial contribution. The third-quarter figures reflect the company as a whole, while Adcomfo’s approval remains a separate regulatory development.

Amneal raised its 2026 fiscal-year revenue guidance to $3.15–$3.25 billion, from the previous range of $3.10–$3.20 billion, according to its statement. It also raised adjusted EBITDA guidance to $800–$815 million from $750–$780 million. Its adjusted diluted earnings-per-share guidance range increased to $1.04–$1.08 from $0.96–$1.06. The revisions raised the company’s annual outlook for all three metrics after its third-quarter results. The statement did not say that the new guidance includes a contribution from Adcomfo or that the European approval changed its financial estimates.

In the market, Amneal shares, which trade under the ticker AMRX, closed at $21.23 on November 16, 2026, according to EL7 data. The information provided does not include verified opening, high or low prices for the same session. The cited close coincided with third-quarter results showing higher revenue and adjusted earnings, alongside a GAAP net loss. The European Commission’s register lists Advanz Pharma Limited as the license holder for Adcomfo. Available data does not identify a separate market response to the European approval.

Open on chart